GRAIL Inc (GRAL) reports a 29% revenue increase and strategic partnerships, despite challenges in market acceptance and competition.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. As part of its bid to transform the future of cancer screening and seize control of ...

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2025.

This reduced false positives from 79 to 51, increasing the positive predictive value of Grail’s Galleri test to 84.2%. The SYMPLIFY study evaluated the multi-cancer early detection test in over 6,000 ...

Artificial intelligence has redefined what it means to measure and understand human intelligence. Once limited to pencil-and-paper exams and subjective interpre ...

Real-time monitoring, AI-powered analytics and connected worker solutions are changing how safety is managed on operational sites. What was once reactive is now predictive – ushering in a new proactiv ...

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsValerie Haertel - Vice President of Investor ...

A simple blood test can pick up cancer cases among patients who have been falsely reassured they do not have the disease, a study suggests. Experts from the University of Oxford and the diagnostics ...